Heghine Khachatryan։ Age-Adjusted D-Dimer Thresholds for Safer and Smarter VTE Rule-Out
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared RPTH’s post on LinkedIn:
”A very important and practical review published in the RPTH Journal highlights a concept that deserves wider clinical attention: age-adjusted D-dimer thresholds.
D-dimer levels naturally increase with age, meaning that the traditional fixed cut-off may lead to false positives and unnecessary imaging, especially in older patients.
Using age-adjusted D-dimer values (Age × 10 µg/L for patients >50 years) helps maintain safety in ruling out VTE while reducing unnecessary CT scans, radiation exposure, and healthcare costs.
This is a clear example of how smarter interpretation of existing diagnostic tests can significantly improve clinical decision-making.”
RPTH Journal shared a post on LinkedIn about a recent article by Tayssir Fatah et al, published in RPTH Journal:
”Is the D-dimer cut-off we use every day actually outdated?
We order D-dimer constantly to rule out VTE. But here’s the problem: D-dimer naturally rises with age.
That means the standard cut-off becomes less specific every year a patient gets older, leading to more false positives and more unnecessary CT scans.
This RPTH review revisits one of the most practical changes in thrombosis diagnostics:
Age-adjusted D-dimer thresholds.
The concept is simple:
For patients >50 years, use Age × 10 μg/L instead of a fixed cut-off.
Why this matters
- It maintains safety for ruling out VTE.
- It reduces unnecessary imaging.
- It cuts radiation exposure and healthcare costs.
- It improves emergency department workflow and patient experience.
Yet despite strong evidence, adoption is still inconsistent worldwide.
So the real question becomes:
- Why hasn’t this become universal practice yet?
- Do your local protocols use age-adjusted D-dimer?
- What barriers still exist in implementation?
Sometimes the most impactful innovation isn’t a new drug, it’s using existing tests smarter.”
Title: Raising the D-dimer bar: a narrative review of the age-adjusted D-dimer threshold
Authors: Tayssir Fatah, Judith Catella, Christophe Nougier, Hamdi Rezigue
Read Full Article on RPTH Journal
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?